Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2014

Open Access 01-12-2014 | Research article

A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease

Authors: Lakkhina Troeung, Sarah J Egan, Natalie Gasson

Published in: BMC Psychiatry | Issue 1/2014

Login to get access

Abstract

Background

The aim of this study was to evaluate the efficacy of a group Cognitive Behavioural Therapy (CBT) treatment for depression and anxiety in Parkinson’s disease (PD).

Methods

A waitlist-controlled trial design was used. Eighteen adults with PD and a comorbid DSM-IV-TR diagnosis of depression and/or anxiety were randomised to either Intervention (8-week group CBT treatment) or Waitlist (8-week clinical monitoring preceding treatment). The Depression, Anxiety, Stress Scale-21 (DASS-21) was the primary outcome. Assessments were completed at Time 1 (pretreatment), Time 2 (posttreatment/post-waitlist) and 1-month and 6-month follow-ups.

Results

At Time 2, participants who received CBT reported greater reductions in depression (M change = -2.45) than Waitlist participants (M change = .29) and this effect was large, d = 1.12, p = .011. Large secondary effects on anxiety were also observed for CBT participants, d = .89, p = .025. All treatment gains were maintained and continued to improve during the follow-up period. At 6-month follow-up, significant and large effects were observed for both depression (d = 2.07) and anxiety (d = 2.26).

Conclusions

Group CBT appears to be an efficacious treatment approach for depression and anxiety in PD however further controlled trials with larger numbers of participants are required.

Trial registration

Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12610000455​066)
Appendix
Available only for authorised users
Literature
1.
2.
Dissanayaka NN, Sellbach A, Matheson S, et al: Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010, 25: 838-845. 10.1002/mds.22833.CrossRefPubMed
3.
Behar M, Srivastava AK, Pandey RM: Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2005, 11: 221-226.CrossRef
4.
Chung TH, Deane KHO, Ghazi-Noori S, Rickards H, Clarke CE: Systematic review of antidepressant therapies in Parkinson’s disease. Parkinsonism Related D. 2003, 10: 59-65. 10.1016/S1353-8020(03)00108-1.CrossRef
5.
Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritisis P, Mavreas V: Efficacy acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010, 10: 49-60. 10.1186/1471-2377-10-49.CrossRefPubMedPubMedCentral
6.
Troeung L, Egan SJ, Gasson N: A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013, 8 (11): e79510-10.1371/journal.pone.0079510.CrossRefPubMedPubMedCentral
7.
Barone P, Poewe W, Albrecht S, et al: Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9: 575-580.CrossRef
8.
Moralez Da Silva T, Munhoz RP, Alvarez C, et al: Depression in Parkinson’s disease: A double-blind, randomized, placebo controlled pilot study of omega-3 fatty-acid supplementation. J Aff Disord. 2008, 111: 351-359. 10.1016/j.jad.2008.03.008.CrossRef
9.
Chen R: Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson’s disease. Mov Disord. 2010, 25: 2272-2273. 10.1002/mds.23266.CrossRefPubMed
10.
Dobkin DR, Menza M, Allen LA, et al: Cognitive behaviour therapy for depression in Parkinson’s disease: a randomized controlled trial. Am J Psychiatry. 2011, 168: 1066-1074.CrossRefPubMedPubMedCentral
11.
Black KJ: A new(old) treatment option for depression in Parkinson’s disease. Am J Psychiatry. 2011, 168: 1015-1016. 10.1176/appi.ajp.2011.11071124.CrossRefPubMed
12.
Dobkin RD, Allen LA, Menza M: A cognitive-behavioral treatment package for depression in Parkinson’s disease. Psychosomatics. 2006, 47: 259-263. 10.1176/appi.psy.47.3.259.CrossRefPubMed
13.
Dobkin RD, Allen LA, Menza M: Cognitive-behavioural therapy for depression in Parkinson’s disease: a pilot study. Mov Disord. 2007, 22: 946-952. 10.1002/mds.21455.CrossRefPubMed
14.
Farabaugh A, Locascio JJ, Yap L, et al: Cognitive-behavioural therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics. 2010, 51: 124-129.PubMed
15.
Feeney F, Egan S, Gasson N: Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clin Psychol. 2005, 9: 31-38. 10.1080/13284200500048240.CrossRef
16.
Gupta R: Treatment of depression in an elderly Asian Indian male: a cognitive behavioural approach. Clin Geronotologist. 2000, 22: 87-90.
17.
Heinrichs N, Hoffman EC, Hofmann SG: Cognitive-behavioural treatment for social phobia in Parkinson’s disease: a single case-study. Cogn Behav Pract. 2001, 8: 328-335. 10.1016/S1077-7229(01)80005-5.CrossRefPubMedPubMedCentral
18.
Laidlaw K, Thompson LW, Dick-Siskin L, Gallagher-Thompson D: Cognitive-Behaviour Therapy with Older People. 2003, Chichester, England: John Wiley & SonsCrossRef
19.
Mohlman J, Reef DH, Chazin D, Ong D, Georgescu B, Tiu J, Dobkin RD: A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clin Case Stud. 2010, 8: 74-90.CrossRef
20.
Thompson LW, Powers DV, Coon DW, Takagi K, McKibbin C, Gallagher-Thompson D: Older adults. Cognitive behavioural group therapy: For specific problems and populations. Edited by: White JR, Freeman AS. 2000, Washington DC: American Psychological Association
21.
A’Campo LEI, Wekking EM, Spliethoff-Kamminga NGA, Le Cessie S, Roos RAC: The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism Relat Disord. 2010, 16: 89-95. 10.1016/j.parkreldis.2009.07.009.CrossRefPubMed
22.
Macht M, Gerlich C, Ellgring H, Schradi M, Rusinol AB, Crespo M, et al: Patient education in Parkinson’s disease: formative evaluation of a standardized program in seven European countries. Patient Educ Couns. 2007, 65: 245-252. 10.1016/j.pec.2006.08.005.CrossRefPubMed
23.
Simons G, Thompson SBN, Pasqualini S: An innovative education programme for people with Parkinson’s disease and their carers. Parkinsonism Relat Disord. 2006, 12: 478-485. 10.1016/j.parkreldis.2006.05.003.CrossRefPubMed
24.
Husaini BA, Cummings S, Kilbourne B, Roback H, Sherkat D, Levine R, Cain VA: Group therapy for depressed elderly woman. Int J Group Psychother. 2004, 54: 295-319. 10.1521/ijgp.54.3.295.40340.CrossRefPubMed
25.
Glass TA, Mendes De Leon CF, Bassuk SS, Berkman L: Social engagement and depressive symptoms in late life: longitudinal findings. J Aging Health. 2006, 18: 604-628. 10.1177/0898264306291017.CrossRefPubMed
26.
Lewinsohn PM, Clarke GN: Psychosocial treatments for adolescent depression. Clin Psychol Rev. 1999, 19: 329-342. 10.1016/S0272-7358(98)00055-5.CrossRefPubMed
27.
Fischer DJ, Himle JA, Hanna GL: Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes. Res Social Work Prac. 1998, 8: 629-636. 10.1177/104973159800800601.CrossRef
28.
Tucker M, Oei TPS: Is group more cost effective than individual cognitive behaviour therapy? The evidence is not solid yet. Behav Cogn Psychother. 2007, 35: 77-91. 10.1017/S1352465806003134.CrossRef
29.
Moher D, Hopewell S, Schulz KF, et al: CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial. BMJ. 2010, 340: c869-10.1136/bmj.c869.CrossRefPubMedPubMedCentral
30.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders (4th ed., text rev.). 2000, Washington, DC: American Psychiatric Association
31.
First MB, Gibbon M, Spitzer RL, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders. 2002, New York: Biometrics Research
32.
Brandt J, Spencer M, Folstein M: The telephone interview for cognitive status. Neuropsy Neuropsy Be. 1988, 1: 111-117.
33.
Sheehan DV, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M: Mini International Neuropsychiatric Interview. 1994, Tampa: University of South Florida
34.
Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, Janavs J, Dunbar G: The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.) A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997, 12: 224-231. 10.1016/S0924-9338(97)83296-8.CrossRef
35.
Lovibond PF, Lovibond SH: The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories. Behav Res Ther. 1995, 33: 335-343. 10.1016/0005-7967(94)00075-U.CrossRefPubMed
36.
Peto V, Jenkinson C, Fitzpatrick R: PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol. 1998, 245: S10-S14. 10.1007/PL00007730.CrossRefPubMed
37.
Beck AT, Brown G, Steer RA, Eidelson JI, Riskin JH: Differentiating anxiety and depression: a test of the cognitive content-specificity hypothesis. J Abnorm Psychol. 1987, 96: 179-183.CrossRefPubMed
38.
Nathan P, Rees C, Smith L: Mood Management Course. 2001, Perth: The West Australian Institute for Psychotherapy Research
39.
Verbeke G, Molenbergs G: Linear Mixed Models for Longitudinal Data. 2000, New York: Springer-Verlag
40.
Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991, 59: 12-19.CrossRefPubMed
41.
Veazey C, Cook KF, Stanley M, Lai EC, Kunik ME: Telephone-administered cognitive behavioural therapy: a case study of anxiety and depression in Parkinson’s disease. J Clin Psychol Med Settings. 2009, 16: 243-253. 10.1007/s10880-009-9167-6.CrossRefPubMed
42.
Rachman S: Rapid and not-so-rapid responses to cognitive behavioural therapy. Clin Psychol-Sci PR. 1999, 6: 293-294. 10.1093/clipsy/6.3.293.CrossRef
43.
National Institute of Health and Clinical Excellence: Depression. The NICE guideline on the treatment management of depression in adults. Updated Version. 2010, Great Britain: British Psychological Society and the Royal College of Psychiatrists
44.
Leentjens AFG, Vreeling FW, Luijckx GJ, Verhey FRJ: SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003, 18: 552-554. 10.1002/gps.865.CrossRefPubMed
45.
Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L: Anxiety disorders, physical illnesses and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol. 2012, 25: 233-239. 10.1177/0891988712466458.CrossRefPubMed
46.
Dobkin RD, Rubino JT, Friedman J, Allen LA, Gara MA, Menza M: Barriers to mental health care utilization in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2013, 26: 105-116. 10.1177/0891988713481269.CrossRefPubMedPubMedCentral
47.
Mohr DC, Spring B, Freedland KE, et al: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom. 2009, 78: 275-284. 10.1159/000228248.CrossRefPubMed
Metadata
Title
A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease
Authors
Lakkhina Troeung
Sarah J Egan
Natalie Gasson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-14-19

Other articles of this Issue 1/2014

BMC Psychiatry 1/2014 Go to the issue

Debate

Etiological classification of depression based on the enzymes of tryptophan metabolism

Research article

Building resilience for future adversity: a systematic review of interventions in non-clinical samples of adults

Research article

Systematic review of management for treatment-resistant depression in adolescents

Research article

Dietary patterns are associated with obesity in Japanese patients with schizophrenia

Research article

Comparison of psychiatric disability on the health of nation outcome scales (HoNOS) in resettled traumatized refugee outpatients and Danish inpatients

Research article

Impaired social decision making in patients with major depressive disorder